Genzyme Will Pursue Cystic Fibrosis Drugs | Chemical & Engineering News
Volume 89 Issue 47 | p. 17 | Concentrates
Issue Date: November 21, 2011

Genzyme Will Pursue Cystic Fibrosis Drugs

Department: Business
Keywords: cystic fibrosis, drug discovery, nonprofits

Sanofi’sGenzyme unit has signed a research agreement with Cystic Fibrosis Foundation Therapeutics to discover drugs to treat people with Delta F508, the most common mutation found in patients with cystic fibrosis. The Delta F508 mutation prevents a protein called CFTR from moving to its proper place at the cell surface, which can impede the flow of fluids in the lungs. Researchers will search libraries at both Genzyme and Sanofi for compounds that help the CFTR protein function correctly.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment